Zenas BioPharma, Inc. (ZBIO)

Zenas BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Sep 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	-	56.86	67.21
Cash & Short-Term Investments	183.93	56.86	67.21
Cash Growth	154.36%	-15.40%	-
Prepaid Expenses	-	1.65	1.24
Other Current Assets	-	1.3	-
Total Current Assets	-	59.8	68.44
Property, Plant & Equipment	-	1.01	1.8
Long-Term Deferred Charges	-	1.39	-
Other Long-Term Assets	-	5.97	4.33
Total Assets	-	68.18	74.58
Accounts Payable	-	5.4	5.82
Accrued Expenses	-	17.01	19.44
Current Portion of Leases	-	0.56	0.72
Current Income Taxes Payable	-	0.3	-
Total Current Liabilities	-	23.26	25.97
Long-Term Debt	-	20.3	-
Long-Term Leases	-	0.26	0.81
Total Liabilities	-	43.82	26.78
Common Stock	-	0	0
Additional Paid-In Capital	-	4.64	1.03
Retained Earnings	-	-230.4	-193.28
Comprehensive Income & Other	-	0.04	-0.04
Total Common Equity	-288.78	-225.72	-192.29
Shareholders' Equity	160.83	24.37	47.8
Total Liabilities & Equity	-	68.18	74.58
Total Debt	0.51	21.11	1.53
Net Cash (Debt)	183.42	35.74	65.68
Net Cash Growth	257.22%	-45.58%	-
Net Cash Per Share	59.36	23.34	44.02
Filing Date Shares Outstanding	7.7	1.58	1.55
Total Common Shares Outstanding	7.7	1.58	1.55
Working Capital	-	36.55	42.48
Book Value Per Share	-182.96	-143.15	-124.11
Tangible Book Value	-288.78	-225.72	-192.29
Tangible Book Value Per Share	-182.96	-143.15	-124.11

Source: S&P Capital IQ. Standard template. Financial Sources.